WO2010059771A1 - Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées - Google Patents

Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées Download PDF

Info

Publication number
WO2010059771A1
WO2010059771A1 PCT/US2009/065058 US2009065058W WO2010059771A1 WO 2010059771 A1 WO2010059771 A1 WO 2010059771A1 US 2009065058 W US2009065058 W US 2009065058W WO 2010059771 A1 WO2010059771 A1 WO 2010059771A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
heterocycloalkyl
optionally substituted
independently
Prior art date
Application number
PCT/US2009/065058
Other languages
English (en)
Inventor
Xin Chen
Meizhong Jin
Andrew Kleinberg
An-Hu Li
Mark J. Mulvihill
Arno G. Steinig
Jing Wang
Original Assignee
Osi Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.
Priority to EP09756112A priority Critical patent/EP2356116A1/fr
Priority to JP2011537600A priority patent/JP2012509342A/ja
Priority to US13/130,113 priority patent/US8592448B2/en
Publication of WO2010059771A1 publication Critical patent/WO2010059771A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • RON recepteur d'origine nantais
  • MSP natural ligand protein
  • MAPK kinase
  • RON can be deregulated in cancer by mechanisms such as over- expression of the receptor and/or the presence of constitutively active splice variants. Inhibition of RON has been shown to lead to a decrease in proliferation, induction of apoptosis and affects cell metastasis. RON overexpression is observed in a variety of human cancers and exhibits increased expression with progression of the disease.
  • MET also known as c-Met
  • c-Met is a receptor tyrosine kinase that is a heterodimeric protein comprising of a 50 kDa ⁇ -subunit and a 145kDa ⁇ -subunit (Maggiora et al., J. Cell Physiol., 173:183-186, 1997). It is activated by binding to its natural ligand HGF (hepatocyte growth factor, also known as scatter factor) and signals via the PI3K and MAPK pathways.
  • HGF hepatocyte growth factor, also known as scatter factor
  • MET can be deregulated in cancer by mechanisms such as autocrine / paracrine HGF activation, over- expression of the receptor, and/or the presence of activating mutations.
  • MET is also implicated in atherosclerosis and lung fibrosis. Inhibition of MET can cause a decrease in cell motility, proliferation and metastasis, as reviewed in, e.g., Chemical & Engineering News 2007, 85 (34), 15-23.
  • Elevated expression of cMET has been detected in numerous cancers including lung, breast, colorectal, prostate, pancreatic, head and neck, gastric, hepatocellular, ovarian, renal, glioma, melanoma, and some sarcomas (see reviews Christensen, J., 2005; Comoglio, P., 2008).
  • cMET gene amplification and resulting overexpression has been reported in gastric and colorectal cancer (Smolen, G., 2005; Zeng Z., 2008).
  • the cMET proto- oncogene has a role in human cancer and its over-expression correlates with poor prognosis.
  • EMT epithelial- mesenchymal transition
  • MET mesenchymal-epithelial transition
  • MET and RON kinases have been shown to play a role in the EMT process (Camp et al., 2007; Grotegut et al., 2006; Wang et al., 2004). It has been documented in vitro that RON and MET can form heterodimers and signal via such RON-MET dimers.
  • cMET and RON are known to interact and influence the activation of one another. Furthermore, co-expression of the two receptors, when compared to each receptor alone, is associated with the poorest clinical prognosis in bladder, CRC, and breast cancer patients. Since co-expression of RON and MET in cancer has been observed, such "cross-talk" may contribute to tumor growth.
  • therapies for use in proliferative disease including treatments for primary cancers, prevention of metastatic disease, and targeted therapies, including tyrosine kinase inhibitors, such as MET and/or RON inhibitors, dual inhibitors, including selective inhibitors, and for potent, orally bioavailable, and efficacious inhibitors, and inhibitors that maintain sensitivity of E cells to epithelial cell directed therapies.
  • tyrosine kinase inhibitors such as MET and/or RON inhibitors
  • dual inhibitors including selective inhibitors, and for potent, orally bioavailable, and efficacious inhibitors, and inhibitors that maintain sensitivity of E cells to epithelial cell directed therapies.
  • the present invention concerns compounds of Formula I, as shown below and defined herein:
  • the invention includes the compounds and pharmaceutically acceptable salts thereof.
  • the invention includes the compounds and salts thereof, and their physical forms, preparation of the compounds, useful intermediates, and pharmaceutical compositions and formulations thereof.
  • compounds of the invention are inhibitors of kinases, including at least one of the c-MET, and RON kinases.
  • compounds of the invention are inhibitors of kinases, including at least one of c-MET, RON, Tie-2, Flt3, FGFR3, AbI, Aurora A, Aurora B, Jak2, AIk, c-Src, IGF-
  • compounds of the invention are selective inhibitors of MET and/or
  • the compound is a selective inhibitor of c-MET and/or RON over other kinase targets, such as KDR.
  • compounds of the invention are useful in treating proliferative disease, particularly cancers, including cancers mediated by c-MET and/or RON, alone or in combination with other agents.
  • the present invention concerns compounds and salts thereof of
  • R 2 is selected from H, halo, -CN, -CF 3 , -NO 2 , C 0-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3- 6 cycloalkylC 0-6 alkyl, C 3-6 heterocycloalkylC 0-6 alkyl, arylC 0-6 alkyl, or heteroarylC 0-6 aI kyl, any of which is optionally substituted with one or more independent G 1 substituents; [22] or R 2 is selected from:
  • R 3 is selected from H, C 1-12 alkyl, R 4 O-C 2-12 alkyl, R 4 R 5 N-C 2-12 alkyl, R 4 S(O) m -C 2-12 alkyl, C 3-12 cycloalkylC 0-12 alkyl, C 3-12 cycloalkenylC 1-12 alkyl, heterocycloalkylC 0-12 alkyl, arylC 0-12 alkyl, heteroarylC 0-12 alkyl, C 1-12 alkylC 3-12 cycloalkyl, C 3-12 cycloalkylC 3-12 cycloalkyl, C 3-12 cycloalkenylC 3- 12 cycloalkyl, heterocycloalkylC 3 _ 12 cycloalkyl, arylC 3 _ 12 cycloalkyl, heteroarylC 3-12 cycloalkyl, C 1- 12 alkyl-heterocycloalkyl, C 3-12 cycloalkyl-
  • G 1 and G 2 are each independently selected from halo, -CN, -CF 3 , -OCF 3 , -NO 2 , oxo, R 6 , C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 3-12 cycloalkylC 0-12 alkyl, heterocycloalkylC 0-12 alkyl, arylC 0-12 alkyl, heteroarylC 0-12 alkyl, -OR 6 , -S(O) m R 6 , -NR 6 R 7 , -SO 2 NR 6 R 7 , -C(0)R b , -C(O)NR 6 R 7 , -C(O)-C(O)NR 6 R 7 , -C(O)OR 6 , -C(O)-C(O)OR 6 , -0C(0)R b , -NR 6 C(O)R b , -NR 6 S(
  • Q 1 is selected from halo, -CN, -NO 2 , oxo, -CF 3 , -OCF 3 , C 1-12 alkyl, arylC 0-12 alkyl, heteroarylC 0-12 alkyl, C 3-12 cycloalkylC 0-12 alkyl, heterocycloalkylC 0-12 alkyl, arylC 3-12 cycloalkyl, heteroarylC 3-12 cycloalkyl, heterocycloalkylC 3-12 cycloalkyl, C 3-12 cycloalkylC 3-12 cycloalkyl, C 1- 12 alkyl-heterocycloalkyl, heterocycloalkyl-heterocycloalkyl
  • Q 2 is selected from halo, -CN, -OH, -NH 2 , -NO 2 , oxo, -CF 3 , -OCF 3 , -CO 2 H, -S(O) m H, C 1-12 alkyl, arylC 0-12 alkyl, heteroarylC 0-12 alkyl, C 3-12 cycloalkylC 0-12 alkyl, heterocycloalkylC 0-12 alkyl, arylC 3-12 cycloalkyl, heteroarylC 3-12 cycloalkyl, heterocycloalkylC 3- 12 cycloalkyl, C 3-12 cycloalkylC 3-12 cycloalkyl, C 1-12 alkylheterocycloalkyl, heterocycloalkyl- heterocycloalkyl, aryl-heterocycloalkyl or heteroaryl-heterocycloalkyl, any of which is optionally substituted with one or more independent
  • each R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R a , R b , and R c is independently selected from H, d.
  • -NR 4 R 5 , -NR 6 R 7 and -NR 11 R 12 is each independently linear structure; or R 4 and R 5 , or R 6 and R 7 , or R 11 and R 12 , respectively, can be taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, or S(0) m ;
  • the present invention concerns compounds and salts thereof of Formula I, more specifically having the formula: [32]
  • X is selected from methyl, ethyl, or methoxy
  • R 1a and R 1e are each independently selected from halo, -CN, C 1-6 alkyl, -CF 3 , -OCF 3 , or -OC 0-6 alkyl;
  • R 1b , R 1c , and R 1d are each independently selected from H, halo, -CN, C 1-6 alkyl, -CF 3 ,
  • alkyl is optionally substituted with -OH, -OC 1-6 alkyl, N(C 0-
  • R 2 is selected from halo, -CN, -CF 3 , -NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-
  • R 2 is selected from:
  • R 3 is selected from H, C 1-12 alkyl, R 4 O-C 2-12 alkyl, R 4 R 5 N-C 2-12 alkyl, R 4 S(O) m -C 2-12 alkyl, C 3-12 cycloalkylC 0-12 alkyl, C 3-12 cycloalkenylC 1-12 alkyl, C 3-12 heterocycloalkylC 0-12 alkyl, arylC 0- 12 alkyl, heteroarylC 0-12 alkyl, C 1-12 alkylC 3-12 cycloalkyl, C 3-12 cycloalkylC 3-12 cycloalkyl, C 3- 12 cycloalkenylC 3-12 cycloalkyl, C 3-12 heterocycloalkylC 3-12 cycloalkyl, arylC 3 _ 12 cycloalkyl, heteroarylC 3-12 cycloalkyl, C 1-12 alkylC 3-12 heterocycloalkyl, C 3-12 cycloo
  • each G 2 is independently selected from halo, -CN, -CF 3 , -OCF 3 , -NO 2 , C 1-12 alkyl, C 2- 12 alkenyl, C 2-12 alkynyl, -OR 6 , -S(O) m R 6 , -NR 6 R 7 , -SO 2 NR 6 R 7 , -C(0)R b , -C(O)NR 6 R 7 ,
  • each Q 1 is selected from halo, -CN, -NO 2 , oxo, -CF 3 , -OCF 3 , C 3-7 cycloalkyl,
  • each R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R a , R b , and R c is independently
  • each -NR 4 R 5 , -NR 6 R 7 and -NR 11 R 12 is independently linear in structure; or R 4 and R 5 , or R 6 and R 7 , or R 11 and R 12 , respectively, can be taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, or S(0) m ;
  • each -CR 8 R 9 and -CR 13 R 14 is independently linear in structure; or R 8 and R 9 , or R 13 and R 14 , respectively, can be taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, or S(0) m ;
  • the present invention concerns compounds and salts thereof of
  • R 1a and R 1e are each independently selected from halo, -CN, C 1-6 alkyl, -CF 3 , -OCF 3 , or -OC 1-6 alkyl;
  • R 1b and R 1d are each independently selected from H, halo, -CN, C 1-6 alkyl, -CF 3 , -
  • R 2 is phenyl or pyridinyl, each substituted by G 1 wherein G 1 is 4-7 heterocycloalkyl optionally substituted with halogen, -OH, -OCH 3 , or C 1-3 alkyl, or G 1 is -C(O)NR 6 R 7 ; wherein each R 6 and R 7 is independently C 0-3 alkyl; or NR 6 R 7 defines a 4-7 heterocycloalkyl optionally substituted by C 1-6 alkyl;
  • R 2 is pyrazolo optionally substituted by G 1 wherein G 1 is 4-6 heterocycloalkyl optionally substituted by halo, -R 6 , oxo, -S(O) m R 6 , -SO 2 NR 6 R 7 , -C(O)R b , -C(O)NR 6 R 7 ,
  • G 1 is C 3-6 cycloalkyl optionally substituted by OH, -OR 6 , oxo, -S(O) m R 6 , -SO 2 NR 6 R 7 , -C(0)R b , -C(O)NR 6 R 7 ,
  • each R 6 , R 7 , R 8 , R 9 , R 10 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl, each independently optionally substituted by halo, -OCF 3 , or -OC 0-3 alkyl; or NR 6 R 7 defines a 4-7 heterocycloalkyl optionally substituted by
  • the present invention concerns compounds and salts thereof of
  • R 1a and R 1e are each independently selected from halo, -CN, C 1-6 alkyl, -CF 3 ,
  • R 1b and R 1d are each independently selected from H, halo, -CN, C 1-6 alky!, -CF 3 , -
  • G 1 is 4 -6heterocycloalkyl optionally substituted by halo, -R 6 , oxo, -S(O) m R 6 ,
  • G 1 is 3-6 cycloalkyl optionally substituted by OH, -OR 6 , oxo, -S(O) m R 6 , -SO 2 NR 6 R 7 ,
  • G 1 is C 1-6 alkyl optionally substituted by -OH, -OR 6 , -R 6 , oxo, -NR 6 R 7 , -C(O)R b ,
  • each R 6 , R 7 , R 8 , R 9 , R 10 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl, each independently optionally substituted by halo, -OCF 3 , or -OC 0-3 alkyl; or NR 6 R 7 defines a 4-
  • the present invention concerns compounds and salts thereof of
  • each R 1b and R 1d is independently H, F, or -OCH 3 ;
  • G 1 is 4 -6heterocycloalkyl optionally substituted by halo, R 6 , oxo, -S(O) m R 6 , -SO 2 NR 6 R 7 ,
  • each R 6 , R 7 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl, each independently optionally substituted by halo, -OCF 3 , or -OC 0-3 alkyl; or NR 6 R 7 defines a 4-
  • the present invention concerns compounds and salts thereof of
  • R 1a and R 1e are both Cl;
  • R 1d is F or -OCH 3 ;
  • G 1 is 4-6 heterocycloalkyl optionally substituted by halo, R 6 , oxo, -S(O) m R 6 , -SO 2 NR 6 R 7 , -C(O)R b , -C(O)NR 6 R 7 , -C(O)-C(O)NR 6 R 7 , -C(O)OR 6 , Or -C(O)-C(O)OR 6 ; [74] wherein each R 6 , R 7 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl, each independently optionally substituted by halo, -OCF 3 , or -OC 0-3 alkyl; or NR 6 R 7 defines a 4 - 7 heterocycloalkyl optionally substituted by C
  • the present invention concerns compounds and salts thereof of Formula I, more specifically having the formula:
  • R 1a and R 1e are both Cl;
  • R 1d is F;
  • G 1 is selected from piperidine, azetidine, or pyrrolidine, each optionally substituted by halo, R 6 , oxo, -S(O) m R 6 , -SO 2 NR 6 R 7 , -C(O)R b , -C(O)NR 6 R 7 , -C(O)-C(O)NR 6 R 7 , -C(O)OR 6 , or -C(O)-C(O)OR 6 ;
  • each R 6 , R 7 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl, each independently optionally substituted by halo, -OCF 3 , or -OC 0-3 alkyl; or NR 6 R 7 defines a 4 _
  • the present invention concerns compounds and salts thereof of
  • Formula I more specifically having the formula: [82] [83] wherein R 1a and R 1e are both Cl; [84] each R 1b and R 1d is independently H, F, Or -OCH 3 ; [85] G 1 is 3-6cycloalkyl substituted by 0-2 substituents independently selected from -OH,
  • each R 6 , R 7 , and R b is independently C 0-5 alkyl or C 3 _ 6 cycloalkyl; or NR 6 R 7 defines a 4-7 heterocycloalkyl optionally substituted by C 1-6 alkyl; and m is 0-2.
  • the present invention concerns compounds and salts thereof of
  • R 1a and R 1e are both Cl; [90] R 1d is F or -OCH 3 ; [91 ] G 1 is 3-6 cycloalkyl substituted by 0-2 substituents independently selected from -OH,
  • each R 6 , R 7 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl; or NR 6 R 7 defines a 4-7 heterocycloalkyl optionally substituted by C 1-6 alkyl; and m is 0-2.
  • the present invention concerns compounds and salts thereof of
  • R 1d is F
  • G 1 is 3-6 cycloalkyl substituted by 0-2 substituents independently selected from -OH,
  • each R 6 , R 7 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl; or NR 6 R 7 defines a 4-7 heterocycloalkyl optionally substituted by C 1-6 alkyl; and m is 0-2.
  • the present invention concerns compounds and salts thereof of
  • each R 1b and R 1d is independently H, F, or -OCH 3 ;
  • G 1 is C 1-6 alkyl substituted by 0-2 substituents independently selected from -OH, -OR 6 ,
  • each R 6 , R 7 , R 8 , R 9 , R 10 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl; or
  • NR 6 R 7 defines a 4-7 heterocycloalkyl optionally substituted by C 1-6 alkyl
  • n is independently 0-2; and each n is independently 0-2.
  • the present invention concerns compounds and salts thereof of
  • R 1d is F or -OCH 3 ;
  • G 1 is C 1-6 alkyl substituted by 0-2 substituents independently selected from -OH, -OR 6 ,
  • each R 6 , R 7 , R 8 , R 9 , R 10 , and R b is independently C 0-5 alkyl or C 3-6 cycloalkyl; or
  • NR 6 R 7 defines a 4-7 heterocycloalkyl optionally substituted by C 1-6 alkyl
  • the present invention concerns compounds and salts thereof of
  • R 1d is F
  • G 1 is C 1-6 alkyl substituted by 0-2 substituents independently selected from -OH, -OR 6 ,
  • each R 6 , R 7 , R 8 , R 9 , R 10 , and R b is independently C 0-3 alkyl or C 3-6 cycloalkyl; or
  • NR 6 R 7 defines a 4-7 heterocycloalkyl optionally substituted by C 1-6 alkyl; [119] m is 0-2; and each n is independently 0-2.
  • the present invention concerns compounds and salts thereof of
  • R 1a and R 1e are each independently selected from halo, -CN, C 1-6 alkyl, -CF 3 ,
  • R 1b and R 1d are each independently selected from H, halo, -CN, C 1-6 alkyl, -CF 3 , -
  • R 2 is phenyl or pyridinyl, each substituted by G 1 ;
  • G 1 is 4-7 heterocycloalkyl optionally substituted with halogen, -OH, -OCH 3 , or C 1-3 alkyl;
  • G 1 is -C(O)NR 6 R 7 ;
  • each R 6 and R 7 is independently C 0-3 alkyl or C 3-6 cycloalkyl; or NR 6 R 7 defines a 4 -
  • the present invention concerns compounds and salts thereof of
  • R 1d is F or methoxy; [132] R 2 is selected from
  • G 1 is selected from piperazine, homopiperazine, morpholine, piperidine, azetidine, or pyrrolidine, each optionally substituted with halogen, -OH, -OCH 3 , or C 1-3 alkyl or C 3-
  • the present invention concerns compounds and salts thereof of
  • R 1a and R 1e are both Cl; [138] R 1d is F or methoxy;
  • R 2 is selected from
  • G 1 is NR 6 R 7 ;
  • each R 6 and R 7 is independently C 0-3 alkyl or C 3-6 cycloalkyl; or NR 6 R 7 defines a ring selected from piperazine, homopiperazine, morpholine, piperidine, azetidine, or pyrrolidine, each optionally substituted with halogen, -OH, -OCH 3 , C 1-3 alkyl, or C 3-6 cycloalkyl.
  • the present invention concerns compounds and salts thereof of Formula I, more specifically having the formula:
  • R 1a and R 1e are each independently selected from halo, -CN, C 1-6 alkyl, -CF 3 ,
  • R 1b and R 1d are each independently selected from H, halo, -CN, C 1-6 alkyl, -CF 3 , -
  • R 2 is selected from [148]
  • R 3 is selected from -R 4 , -C(O)R a , R 4 O-C 0-12 alkylC(O)-, R 4 R 5 N-C 0-
  • each R a , R 4 , and R 5 is independently C 0-3 alkyl or C 3-6 cycloalkyl; or NR 4 R 5 defines a 4-
  • each m is independently 0-2.
  • Formula I include any combination of such variables or variable subsets.
  • the invention includes a compound of Formula I or a pharmaceutically acceptable salt thereof, in any of the above recitations, which further exhibits inhibition of c-MET in a cellular assay with an IC 50 of about 100 nM or less.
  • the invention includes a compound of Formula I or a pharmaceutically acceptable salt thereof, in any of the above recitations, which further exhibits inhibition of Ron in a cellular assay with an IC 50 of about 200 nM or less.
  • the invention includes a compound of Formula I or a pharmaceutically acceptable salt thereof, in any of the above recitations, which further exhibits inhibition of c-MET in a cellular assay with an IC 50 of about 100 nM or less and inhibition of
  • Ron in a cellular assay with an IC 50 of about 200 nM or less is a cellular assay with an IC 50 of about 200 nM or less.
  • the invention includes a compound of Formula I or a pharmaceutically acceptable salt thereof, in any of the above recitations, which further exhibits inhibition of c-MET in a cellular assay with an IC 50 of about 100 nM or less and inhibition of
  • the invention includes any of the compound examples herein and pharmaceutically acceptable salts thereof.
  • the invention includes the compounds and salts thereof, and their physical forms, preparation of the compounds, useful intermediates, and pharmaceutical compositions and formulations thereof.
  • Compounds described can contain one or more asymmetric centers and may thus give rise to stereoisomers.
  • the present invention includes any stereoisomers, even if not specifically shown, individually as well as mixtures, geometric isomers, and pharmaceutically acceptable salts thereof. Where a compound or stereocenter is described or shown without definitive stereochemistry, it is to be taken to embrace all possible isomers and mixtures thereof. Thus, a material sample containing a mixture of stereoisomers would be embraced by a recitation of either of the stereoisomers or a recitation without definitive stereochemistry. Also contemplated are any cis/trans isomers or tautomers of the compounds described.
  • the compounds may be amorphous or may exist or be prepared in various crystal forms or polymorphs, including solvates and hydrates.
  • a recitation of a compound per se is taken to embrace that compound regardless of any unspecified stereochemistry, physical form and whether or not associated with solvent or water.
  • a recitation of a compound also includes any isotopes thereof.
  • the compound of formula (I) of the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
  • the invention includes the intermediates and synthetic methods described herein.
  • the compounds of the Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to those of ordinary skill in the art.
  • the starting materials used herein are commercially available or may be prepared by routine methods known in the art (such as those methods disclosed in standard reference books such as the COMPENDIUM OF ORGANIC SYNTHETIC METHODS, Vol. I-VI (published by Wiley-lnterscience)). Preferred methods include, but are not limited to, those described below.
  • Preferred methods include, but are not limited to, those described below.
  • Compounds of Formula I can be prepared from N-A as in Scheme 1 , wherein R 1 and R 2 are as defined previously and A 11 is halogen such as Cl, Br, or I and B(OR) 2 is a suitable boronic acid/ester.
  • a compound of Formula N-A is reacted with a suitable boronic acid/ester (R 2 -B(OR) 2 ) in a suitable solvent via typical Suzuki coupling procedures.
  • Suitable solvents for use in the above process include, but are not limited to, ethers such as THF, glyme, dioxane, dimethoxyethane, and the like; DMF; DMSO; MeCN; alcohols such as MeOH, EtOH, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as DCM or chloroform (CHCl3). If desired, mixtures of these solvents can be used; however, preferred solvents are dimethoxyethane/water and dioxane/water.
  • the above process can be carried out at temperatures between about -78°C and about 120°C. Preferably, the reaction is carried out between 60°C and about 100°C.
  • Nl-A can be prepared as in Scheme 2, wherein R 1 is as defined previously and A 11 is halogen such as Cl, Br, or I.
  • Nl-A can be reacted with a suitable methyl source in the presence of a Lewis acid in a suitable solvent.
  • suitable methyl source for use in the above process include, but are not limited to Me 3 AI, Me 2 Zn, Me 2 AICI, methyl Grignard reagents.
  • a preferred methyl source is Me 2 Zn.
  • the methyl source may also be generated in situ, such as by reacting a methyl Grignard reagent with zinc chloride and using the resulting reagent without isolation for the above process.
  • Suitable Lewis acids for use in the above process include, but are not limited to BF 3 « OEt 2 , AICI 3 , TiCI 4 , and the like.
  • a preferred Lewis acid is BF 3 « OEt 2 .
  • Suitable solvents for use in the above process include, are not limited to, ethers such as THF, glyme, and the like; DMF; DMSO; MeCN; toluene; cyclohexane, and chlorinated solvents such as DCM or chloroform (CHCl 3 ). If desired, mixtures of these solvents can be used; however, a preferred solvent is THF.
  • the above process can be carried out at temperatures between about -78°C and about 120°C. Preferably, the reaction can be carried out between 40°C and about 70°C. An excess amount of the methyl source and Lewis acid are preferably used.
  • Compounds of Formula Nl-A can be prepared as in Scheme 3, wherein R 1 is as defined previously and A 11 is halogen such as Cl, Br, or I.
  • IV-A is treated with benzaldehyde V in a suitable solvent in the presence of a suitable base at a suitable reaction temperature.
  • suitable solvents for use in the above process include, but are not limited to, ethers such as THF, glyme, and the like; DMF, DMSO; MeCN; chlorinated solvents such as DCM or chloroform (CHCl 3 ); and alcohols such as MeOH, EtOH, isopropanol, or trifluoroethanol.
  • a preferred solvent is MeOH.
  • Suitable bases for use in the above process include, but are not limited to, KOH, NaOH, LiOH, KOtBu, NaOtBu and NaHMDS and the like.
  • a preferred base is KOH.
  • the above process can be carried out at temperatures between about -78°C and about 120°C. Preferably, the reaction is carried out between 20°C and about 60°C.
  • the above process to produce compounds of the present invention is preferably carried out at about atmospheric pressure although higher or lower pressures can be used. Substantially equimolar amounts of reactants are preferably used although higher or lower amounts can be used.
  • Compounds of Formula I can be prepared as in Scheme 4, wherein R 1 and R 2 are as defined previously, A 11 is halogen such as Cl, Br, or I, and B(OR) 2 is a suitable boronic acid/ester.
  • Compound N-B can be reacted with a suitable coupling partner (R -A ) in a suitable solvent via typical Suzuki coupling procedures.
  • Suitable solvents for use in the above process include, but are not limited to, ethers such as THF, glyme, dioxane, dimethoxyethane, and the like; DMF; DMSO; MeCN; alcohols such as MeOH, EtOH, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as DCM or chloroform (CHCl 3 ). If desired, mixtures of these solvents can be used, however, a preferred solvent is dimethoxyethane/water.
  • the above process can be carried out at temperatures between about -78°C and about 120°C. Preferably, the reaction is carried out between 60°C and about 100°C.
  • Compounds of Formula N-B can be prepared as in Scheme 5, wherein R 1 is as defined previously, A 11 is halogen such as Cl, Br, or I, and B(OR) 2 is a suitable boronic acid/ester.
  • R 1 is as defined previously
  • a 11 is halogen such as Cl, Br, or I
  • B(OR) 2 is a suitable boronic acid/ester.
  • a compound of Formula N-A can be reacted with a suitable coupling partner (Bis(pinacolato)diboron or Pinacolborane)) in a suitable solvent under Palladium catalysis.
  • Suitable solvents for use in the above process include, but are not limited to, ethers such as THF, glyme, dioxane, dimethoxyethane, and the like; DMF; DMSO; MeCN; alcohols such as MeOH, EtOH, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as DCM or chloroform (CHCl 3 ). If desired, mixtures of these solvents can be used; however, a preferred solvent is THF or dioxane.
  • the above process can be carried out at temperatures between about -78°C and about 120°C. Preferably, the reaction is carried out between 60°C and about 100°C.
  • the above process is preferably carried out at about atmospheric pressure although higher or lower pressures can be used. Substantially equimolar amounts of reactants used although higher or lower amounts can be used if desired.
  • a compound of Formula N-A is reacted with a chiral auxiliary in the presence of a coupling reagent to provide both ll-A-dia-A and ll-A-dia-B, which are separated by chromatography.
  • Suitable chiral auxiliaries for use in the above process include, but are not limited to amino acids and their derivatives, (1 S)-(+)- camphor-10-sulfonic acid, (1 /?)-(-)-camphor-10-sulfonic acid and the like.
  • a preferred chiral auxiliary is Fmoc-L-Leucine.
  • Suitable solvents for use in the above process included, but are not limited to, ethers such as THF, glyme, dioxane, dimethoxyethane, and the like; DMF; DMSO; MeCN; alcohols such as MeOH, EtOH, isopropanol, trifluoroethanol, and the like; and chlorinated solvents such as DCM or chloroform (CHCl 3 ). If desired, mixtures of these solvents can be used, however, a preferred solvent is DMF.
  • the suitable coupling reagents for use in the above process include, but are not limited to DCC, EDC, TBTU, HBTU and the like. A preferred coupling reagent is TBTU.
  • the above process can be carried out at temperatures between about -78°C and about 120°C.
  • the reaction is carried out between 0°C and about 60°C.
  • the above process is preferably carried out at about atmospheric pressure although higher or lower pressures can be used if desired.
  • Substantially equimolar amounts of reactants are preferably used although higher or lower amounts can be used if desired.
  • both ll-A-dia-A and ll-A-dia-B are reacted separately with a suitable boronic acid/ester (R 2 -B(OR) 2 ), to provide both l-ena-A and l-ena-B, via typical
  • a chiral auxiliary instead of covalently attaching a chiral auxiliary to compound N-A one may form diastereomeric salts that may be separated by crystallization. Neutralization of the separated diastereomeric salts provides the separated enantiomers of N-A.
  • Suitable chiral auxiliaries include, but are not limited to amino acids and their derivatives, (1 S)-(+)-camphor-10-sulfonic acid, (1 /?)-(-)-camphor-10-sulfonic acid and the like.
  • the enantiomerically pure isomers l-ena-A and l-ena-B can be prepared as in Scheme 7 individually from corresponding enantiomerically pure ll-A-ena-A and ll-A-ena- B through Suzuki coupling reactions.
  • Enantiomerically pure ll-A-ena-A and ll-A-ena-B can be prepared from separation of racemic mixture N-A by a chiral chromatography as in Scheme 7.
  • the suitable system for separation of ll-A-ena-A and ll-A-ena-B by chromatography can be, but is not limited to, chiral HPLC (high performance liquid chromatography) systems, chiral SFC (supercritical fluid chromatography) systems and the like.
  • both ll- A-ena-A and ll-A-ena-B can be reacted individually with a suitable boronic acid/ester (R 2 - B(OR) 2 ), to provide both l-ena-A and l-ena-B, via typical Suzuki coupling procedures as in Scheme 1.
  • R 2 - B(OR) 2 suitable boronic acid/ester
  • the synthetic route/sequence can be modified as desired for the preparation of a given compound.
  • Group R 2 can be installed on compound IV-A under conditions similar to Schemes 1 , 5, and 4.
  • the resulting compound can be treated with an appropriate benzaldehyde under conditions similar to Scheme 3, followed by introduction of a methyl group similar to Scheme 2.
  • pyrrolo[2,3-b]pyrazine cores can be substituted for the depicted pyrrolopyridines.
  • a skilled artisan will realize that the reactions shown in Schemes 1 , 4-7 can be conducted under similar conditions with compounds in which the methyl group shown is replaced by other alkyl or alkoxy groups within the scope defined for the variable X.
  • the multiplicities in 1 H NMR spectra are abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), m c (centered multiplet), br or broad (broadened), AA'BB'.
  • the signal multiplicities in 13 C NMR spectra were determined using the DEPT135 pulse sequence and are abbreviated as follows: + (CH or CH 3 ), - (CH 2 ), C quart (C). Reactions were monitored by thin layer chromatography (TLC) on silica gel 60 F 254 (0.2 mm) precoated aluminum foil and visualized using UV light.
  • Mass-directed HPLC purification of compounds was performed on a Waters system composed of the following: 2767 Sample Manager, 2525 Binary Gradient Module, 600 Controller, 2996 Diode Array Detector, Micromass ZQ2000 for ionization, Phenomenex Luna 5 ⁇ C18(2) 100 A 150 x 21.2mm 5 ⁇ column with mobile phases of 0.01% Formic Acid Acetonitrile (A) and 0.01% Formic Acid in HPLC water (B), a flow rate of 20 mL/min, and a run time of 13 min.
  • LC-MS data was collected on ZQ2, ZQ3, or UPLC-ACQUITY.
  • ZQ2 is an Agilent 1100 HPLC equipped with a Gilson 215 Liquid Handler, Gilson 819 Injection Module, and Waters Micromass ZQ2000 for ionization.
  • ZQ3 is an Agilent 1 100 HPLC equipped with an HP Series 1 100 auto injector and Waters Micromass ZQ2000 for ionization. Both systems use the Xterra MS C18, 5 ⁇ particle size, 4.6 x 50 mm with a mobile phase of Acetonitrile (A) and 0.01 % Formic Acid in HPLC water (B).
  • the flow rate is 1.3 mL/min, the run time is 5 min, and the gradient profiles are 0.00 min 5%A, 3.00 min 90%A, 3.50 min 90%A, 4.00 min 5%A, 5.00 min 5%A for polar_5min and 0.00 min 25%A, 3.00 min 99%A, 3.50 min 99%A, 4.00 min 25%A, 5.00 min 25%A for nonpolar_5min.
  • All Waters Micromass ZQ2000 instruments utilized electrospray ionization in positive (ES+) or negative (ES-) mode.
  • the Waters Micromass ZQ2000 instruments from ZQ2 and ZQ3 can also utilize atmospheric pressure chemical ionization in positive (AP+) or negative (AP-) mode.
  • the Waters U PLC-ACQU ITY system consists of an ACQUITY sample manager attached to ACQUITY SQ MS and ACQUITY PDA detectors. It uses an ACQUITY UPLC BEH ® C18 2.1 ⁇ 50mm 1.7 ⁇ m column with a mobile phase of 0.1 % formic acid in water (A) and 0.1 % formic acid in acetonitrile (B). The flow rate is 1.0 mL/min, run time is 2 min, and the gradient profile is 0.00 min 95%A, 1.50 min 1 %A, 1.85 min 1 %A, 2.0 min 95% A for analytical. UV detection is at 254 nm, and the MS utilizes electrospray ionization in positive mode (ES+).
  • ES+ electrospray ionization in positive mode
  • HPLC purification of compounds was performed on a Waters system consisting of a 2767 Sample Manager, 1525EF Binary Pump, and a 2487 Dual ⁇ Absorbance Detector.
  • the system uses Phenomenex Luna C18(2), 5 ⁇ particle size, 50 x 21.2 mm columns with a mobile phase of Acetonitrile/0.25% Formic Acid and HPLC water/0.25% Formic Acid.
  • a Gilson system (“Gilson HPLC”) consisting of a 215 Liquid Handler, 819 Injection Module, a 322 Pump, and a 155 UV/VIS dual wavelength detector set to 254 and 210 nm was used.
  • This system uses Phenomenex Luna C18(2), 5 ⁇ particle size, 50 x 21.2 mm or 60 x 21.2 mm columns with a mobile phase of Acetonitrile and 0.1 % Formic Acid in HPLC water. The flow rate is 15 mL/min and the run time is 25 min.
  • the HPLC system for determination of enantiomeric purity consists of an Agilent 1100 HPLC and Chiralcel or Chiralpak 4.6x150 mm columns (Daicel Chemical Ind., Ltd.), eluting with acetonitrile/water mixtures. All melting points were determined with a Mel-Temp Il apparatus and are uncorrected. Elemental analyses were obtained by Atlantic Microlab, Inc., Norcross, GA.
  • the rapidly stirred biphasic mixture was cooled to -7 °C and TEMPO (1.54 g, 0.0100 mol) was added.
  • a solution of 0.81 M sodium hypochlorite (823 ml_, 0.66 mol) saturated with sodium bicarbonate (75 g) was added dropwise over a period of 1 h while maintaining the temperature below -2 °C.
  • the reaction mixture was stirred for 30 min.
  • the two layers separated and the DCM layer was washed with aq. solution of sodium thiosulfate.
  • the DCM layer was dried (Na 2 SO 4 ) and concentrated on rotary evaporator without using vacuum (aldehyde is volatile) to give the title compound as a solid, mp.
  • Example 1 3-[1-(2,6-Dichlorophenyl)ethyl]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H- pyrrolo[2,3-b]pyridine
  • Example 2 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)- 1 H-pyrrolo[2,3-b]pyridine.
  • Example 5 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -N- methylbenzamide:
  • Example 6 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -N- (2-methoxyethyl)benzamide:
  • Example 7 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -N- (2-morpholin-4-ylethyl)benzamide:
  • Example 10 N-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ phenyl)acetamide:
  • Example 13 (4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]--//-/-pyrrolo[2,3-b]pyridin-5- yl ⁇ phenyl)morpholin-4-ylmethanone
  • Example 14 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ benzamide:
  • Example 15 (4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ phenyl)-(4-methylpiperazin-1-yl)methanone
  • Example 16 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-5-[4-(4-methylpiperazin-1- yl)phenyl]-1H-pyrrolo[2,3-b]pyridine:
  • Example 20 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -
  • Example 22 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -
  • Example 28 4-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-piperidine-1-carboxylic acid dimethylamide
  • the solution was loaded into an SCX cartridge, washed with MeOH (30 mL) and ejected with 2M NH 3 in MeOH (10 mL).
  • the filtrate was concentrated in vacuo, redissolved in dioxane, and 4M HCl in dioxane (1 mL) was added.
  • the solution was heated to 40 °C for 2 h.
  • the material was loaded into an SCX cartridge, washed with MeOH (30 mL) and ejected with 2M NH 3 in MeOH (10 mL).
  • the filtrate was concentrated in vacuo, redissolved in MeOH (0.5 mL) and purified via HPLC. The fractions containing the pure product were concentrated in vacuo to afford the title compound as a white solid.
  • Example 34 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -
  • Example 35 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -
  • Example 36 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -
  • Example 38 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -
  • Examples 39-44 were synthesized according to the procedure described for synthesis of Example 38.
  • Example 39 1-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -3,6-dihydro-2H-pyridin-1-yl)-ethanone
  • Example 40 (R)-1-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl ⁇ -3,6-dihydro-2H-pyridin-1-yl)-2-hydroxypropan-1-one
  • Example 42 1-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -3,6-dihydro-2H-pyridin-1-yl)-2-hydroxy-2-methylpropan-1-one
  • Example 43 1-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -3,6-dihydro-2H-pyridin-1-yl)-2-hydroxyethanone
  • Example 46 4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl ⁇ -
  • Example 48 was synthesized according to the procedure described for synthesis of
  • Example 50 3-[1-(2,6-Dichloro-3-fluorophenyl)-ethyl]-5-[1-(1-methanesulfonyl- piperidin-4-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridine
  • Example 50 was synthesized according to the procedure described for synthesis of
  • Example 51 4-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-piperidine-1-carboxylic acid methylamide
  • Example 51 was synthesized according to the procedure described for synthesis of
  • Example 52 4-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-piperidine-1 -sulfonic acid amide
  • the organic solvent was removed in vacuo, and the material was transferred to a separatory funnel, extracting with DCM and water.
  • the organic layer was concentrated in vacuo, redissolved in dioxane, and 4M HCl in dioxane (1 ml.) was added.
  • the solution was heated to 45 °C for 3 h.
  • the solvents were removed on the corrosive pump, and the material was dry-loaded onto silica gel for column chromatography, eluting with 3-6% (7N NH 3 in MeOH) / DCM.
  • the fractions containing the pure product were concentrated in vacuo to afford the title compound as a yellow solid.
  • Example 57-58 were synthesized according to the procedure described for synthesis of Example 56.
  • Example 58 1-[3-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-
  • Example 60 2-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-2-methylpropionic acid methyl ester
  • Example 61 2-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-2-methylpropionic acid
  • Example 62 2-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-N-methylisobutyramide
  • Example 63 were synthesized according to the procedure described for synthesis of Example 62. [361] Example 63: 2-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-N,N-dimethylisobutyramide
  • Example 64 2-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1 -yl)-isobutyramide
  • Example 65 2-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-2-methylpropan-1-ol
  • Example 66 3-[(S)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-5-(1 ,2,5,6-tetrahydropyridin- 3-yl)-1H-pyrrolo[2,3-b]pyridine
  • the reaction mixture was directly loaded onto Prep TLC (5% MeOH in DCM) to afford 10 mg crude product.
  • the crude product was dissolved in DCM (2 mL) and treated with 4 M HCl in dioxane for 2 h at rt.
  • the resulting solution was loaded onto a Prep TLC (20x20 cm plate, silica gel 500 ⁇ M, 5% 7 N NH 3 in MeOH in DCM) to afford the desired product.
  • Example 68 3-[(S)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-5-pyridin-4-yl-1H-pyrrolo[2,3- b]pyridine: [376]
  • Example 68 was synthesized according to the Suzuki coupling method described above for the synthesis of example 66, using ((S)-1- ⁇ 5-Bromo-3-[(S)-1-(2,6-dichloro-3- fluorophenyl)ethyl]pyrrolo[2,3-b]pyridine-1-carbonyl ⁇ -3-methyl-butyl)-carbamic acid 9H-fluoren- 9-ylmethyl ester and 4-(4,4,5,5-Tetramethyl[1 ,3,2]dioxaborolan-2-yl)pyridine, except that the crude product was purified by HPLC.
  • Example 69 was synthesized according to Suzuki coupling method described above for synthesis of example 66, using ((S)-1- ⁇ 5-Bromo-3-[(S)-1-(2,6-dichloro-3- fluorophenyl)ethyl]pyrrolo[2,3-b]pyridine-1 -carbonyl ⁇ -3-methylbutyl)carbamic acid 9H-fluoren- 9-ylmethyl ester and 4-[4-(4,4,5,5-Tetramethyl[1 ,3,2]dioxaborolan-2-yl)benzoyl]piperazine-1- carboxylic acid tert-butyl ester. The crude material was purified by HPLC.
  • Example 71 4-(4- ⁇ 3-[1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5- yl ⁇ -pyrazol-1-yl)-piperidine-1-carbaldehyde
  • Example 71 was synthesized from 3-[(S)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-(1- piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine (example 80) according to the method described for the synthesis of example 47.
  • 1 H NMR 400 MHz, CD 3 OD
  • Example 72 4-(4- ⁇ 3-[(S)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin- 5-yl ⁇ -pyrazol-1-yl)-piperidine-1-carboxamide
  • Example 72 was synthesized from 3-[(S)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-(1- piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine (example 80) according to the method described for the synthesis of example 49.
  • 1 H NMR 400 MHz, CD 3 OD
  • 2.04 (br. s., 2 H), 2.17 (br. s., 2 H), 3.15 (br. s., 2 H), 4.08-4.31 (m, 2 H), 4.53 (br.
  • Example 73 was synthesized from 3-[(S)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-(1- piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine (example 80) according to the method described for the synthesis of example 50.
  • Example 75 2-(4- ⁇ 3-[(S)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl ⁇ -pyrazol-1-yl)-acetamide
  • Examples 76-79 were synthesized according to the procedure described for synthesis of Example 75.
  • Example 76 2-(4- ⁇ 3-[(S)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl ⁇ -pyrazol-1-yl)-N-methylacetamide
  • Example 77 2-(4- ⁇ 3-[(S)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl ⁇ -pyrazol-1-yl)acetamide
  • Example 80 3-[(S)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-5-(1-piperidin-4-yl-1H- pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
  • Example 82 4-(4- ⁇ 3-[(R)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl ⁇ -pyrazol-1-yl)-piperidine-1-carbaldehyde
  • Example 82 was synthesized from 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-(1- piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]py ⁇ dine (example 81 ) according to the method described for the synthesis of example 47.
  • 1 H NMR (400 MHz, CD 3 OD): ⁇ 1.85-2.08 (m, 5
  • Example 83 3-[(R)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-5-[1-(1-methane- sulfonylpiperidin-4-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridine
  • Example 83 was synthesized from 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-(1- piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine (example 81 ) according to the method described for the synthesis of example 50.
  • Example 84 4-(4- ⁇ 3-[(R)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl ⁇ -pyrazol-1-yl)-piperidine-1-carboxamide
  • Example 84 was synthesized from 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-(1- piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine (example 81 ) according to the method described for the synthesis of example 49.
  • Example 85 2-(4- ⁇ 3-[(S)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl ⁇ -pyrazol-1-yl)-2-methylpropan-1-ol
  • Example 86 frans-4-(4- ⁇ 3-[(1 S)-1-(2,6-dichloro-3-fluorophenyl)ethyl]-1H-pyrrolo[2,3- b]pyridin-5-yl ⁇ -1H-pyrazol-1-yl)cyclohexanol
  • the cap was sealed and the vial was evacuated and backfilled with nitrogen (3x). After that, the vial was heated at 90 °C for 2 h.
  • the reaction mixture was partitioned between EtOAc/H 2 O (15 ml/10 ml).
  • the aqueous phase was extracted with EtOAc (10 ml).
  • the combined organic extracts were washed with water (10 ml) and brine (10 ml), dried over MgSO4, filtered, and concentrated in vacuo to give a brown oil that was purified by prep. TLC eluting with 4% MeOH/DCM to give the title compound.
  • compounds of the invention are inhibitors of kinases, including at least one of the c-MET, and RON kinases.
  • compounds of the invention are inhibitors of kinases, including at least one of c-MET, RON, Tie-2, Flt3, FGFR3, AbI, Aurora A, Aurora B, Jak2, AIk, c-Src, IGF-
  • compounds of the invention are selective inhibitors of c-MET and/or
  • the compound is a selective inhibitor c-MET and/or RON over other kinase targets, such as KDR.
  • compounds of the invention inhibit epithelial to mesenchymal transition.
  • MKN45 cells were plated in Corning 3917 96-well white tissue culture treated plates in growth medium (RPMI, 10% FCS) at a density of 5000 cells/well in a total volume of 135 ⁇ l_ and incubated at 37 °C, 5% CO 2 , 95% humidity overnight. The following day, one-tenth volume of a 10X concentration of compounds was added to the wells in an 8- point dilution series.
  • the dilution series was composed of an initial 1 :5 dilution of a 10 mM stock of compound in DMSO, followed by serial 1 :4 dilutions in DMSO, then a 1 :20 dilution in growth medium prior to the 1 :10 dilution into the cell plate.
  • Final DMSO concentration on the cells was 0.1 %, there were control wells treated with both 0.1% DMSO and no DMSO.
  • the typical dilution range is 10 ⁇ M to 0.6 nM.
  • IC 50 values of exemplary compounds of the present invention determined in a cell proliferation assay using the MKN45 cell line according to the procedures described herein in at least duplicate experiments are abbreviated as follows and are shown in Table 2: A, IC50 ⁇ 0.1 ⁇ M; B, 0.1 ⁇ M ⁇ IC 50 ⁇ 1 ⁇ M; C, 1 ⁇ M ⁇ IC 50 ⁇ 10 ⁇ M; D, IC 50 > 10 ⁇ M; ND, not determined.
  • the Example # of Table 2 corresponds to the compound example number as illustrated in the Examples section.
  • the cellular activity of the compounds of the present invention may be determined by the following procedure.
  • MKN45 cells were plated in Falcon 3072 96-well plates in growth media (RPMI, 10% FBS, 1% L-glutamine) at a density of 5000 cells/well and incubated at 37 °C, 5% CO 2 overnight. The following day, one-tenth volume of a 10X concentration of compounds was added to the wells in a 6-point dilution series. The dilutions series was composed of an initial 1 :5 dilution in DMSO, followed by a 1 :10 dilution in growth media, for a final DMSO concentration on cells of 0.5%. Control wells were treated with 0.5% DMSO.
  • the typical range of dilution was 10 ⁇ M to 3 nM.
  • plates were incubated for four hours at 37 °C, 5% CO 2 . Plates were then washed in PBS, and lysed in triton-based lysis buffer. Lysates were transferred to a precoated capture plate made by Biosource (Cat # KHO0281 ).
  • the phosphorylated c-MET levels were measured by incubating with a rabbit polyclonal antibody against phosphorylated c-MET ([pYpYpYI 230/1234/1235]) followed by an anti-rabbit antibody conjugated to HRP. Signal was measured on a Wallac Victor plate reader at 450 nm.
  • the DMSO signal of the control wells was defined as 100% and the percent of inhibition of phosphorylated c-Met was expressed as percent of control.
  • IC50 values were determined from the percent of control data using a standard four-parameter model.
  • IC50 values of exemplary compounds of the present invention determined in a c- MET cell mechanistic assay using the MKN45 cell line according to the procedures described herein in at least duplicate experiments are abbreviated as follows and are shown in Table 3: A, IC 50 ⁇ 0.1 ⁇ M; B, 0.1 ⁇ M ⁇ IC 50 ⁇ 1 ⁇ M; C, 1 ⁇ M ⁇ IC 50 ⁇ 10 ⁇ M; D, IC 50 > 10 ⁇ M; ND, not determined.
  • the Example # of Table 3 corresponds to the compound example number as illustrated in the Examples section.
  • the compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and they are useful in the treatment and/or prevention of various diseases and conditions.
  • compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, AbI, Aurora-A, Aurora B, AIk, Jak2, BIk, c-Raf, cSRC, Src, PRK2,
  • Ron, c-Met, KDR, PAK1 , PAK2, and TAK1 can be used in the treatment of proliferative diseases, such as, but not limited to, cancer.
  • the invention includes a method of treating cancer comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention.
  • the invention includes a method of treating cancer comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention, wherein at least one additional active anti-cancer agent is used as part of the method.
  • the additional agent(s) is an EGFR inhibitor and/or an IGF-
  • the compounds of Formula I of the present invention are useful in the treatment of a variety of cancers, including, but not limited to, solid tumor, sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, hematopoietic malignancy, and malignant ascites.
  • the cancers include, but not limited to, lung cancer, bladder cancer, pancreatic cancer, kidney cancer, gastric cancer, breast cancer, colon cancer, prostate cancer (including bone metastases), hepatocellular carcinoma, ovarian cancer, esophageal squamous cell carcinoma, melanoma, an anaplastic large cell lymphoma, an inflammatory myofibroblastic tumor, and a glioblastoma.
  • the above methods are used to treat one or more of bladder, colorectal, nonsmall cell lung, breast, or pancreatic cancer. In some aspects, the above methods are used to treat one or more of ovarian, gastric, head and neck, prostate, hepatocellular, renal, glioma, glioma, or sarcoma cancer.
  • the invention includes a method of treating a cancer, such as those above, which is mediated at least in part by c-MET and/or RON comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention.
  • the cancer is mediated at least in part by amplified c-
  • the compound is a dual RON and c-MET inhibitor, and can be a selective inhibitor.
  • the invention includes a method, including the above methods, wherein the compound is used to inhibit EMT.
  • dosage levels on the order of from about 0.01 mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 7g per patient per day.
  • inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.
  • the invention provides a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of the invention, which is formulated with or without one or more pharmaceutical carriers.
  • compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds represented by Formula I, or prodrugs, metabolites, or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion.
  • the compound represented by Formula I, or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • a pharmaceutical composition of this invention may include a pharmaceutically acceptable carrier and a compound, or a pharmaceutically acceptable salt, of Formula I.
  • the compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • any convenient pharmaceutical media may be employed.
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
  • a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about 1 mg to about 2g of the active ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or 1000mg.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
  • Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods.
  • a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds. [463] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.
  • connection of compound name moieties are at the rightmost recited moiety. That is, the substituent name starts with a terminal moiety, continues with any bridging moieties, and ends with the connecting moiety.
  • substituent name starts with a terminal moiety, continues with any bridging moieties, and ends with the connecting moiety.
  • hetarylthioC 1-4 alkyl has a heteroaryl group connected through a thio sulfur to a C 1-4 alkyl that connects to the chemical species bearing the substituent.
  • C 0-12 alkyl is used to mean an alkyl having 0-12 carbons
  • C o alkyl means a single covalent chemical bond if C o alkyl is a connecting moiety, and a hydrogen if Coalkyl is a terminal moiety.
  • alkyl includes both branched and straight chain alkyl groups. Typical alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl, eicosyl, and the like.
  • halo refers to fluoro, chloro, bromo, or iodo.
  • cycloalkyl refers to a 3-12 carbon mono-cyclic, bicyclic, or polycyclic aliphatic ring structure, optionally substituted with for example, alkyl, hydroxy, oxo, and halo, such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, 2- hydroxycyclopentyl, cyclohexyl, 4-chlorocyclohexyl, cycloheptyl, cyclooctyl, and the like.
  • Cycloalkyl can be bicycloalkyl, polycycloalkyl or spiroalkyl.
  • bicycloalkyl and "polycycloalkyl” refer to a structure consisting of two or more cycloalkyl moieties that have two or more atoms in common. If the cycloalkyl moieties have exactly two atoms in common they are said to be “fused”. Examples include, but are not limited to, bicyclo[3.1.0]hexyl, perhydronaphthyl, and the like. If the cycloalkyl moieties have more than two atoms in common they are said to be "bridged”. Examples include, but are not limited to, bicyclo[2.2.1]heptyl ("norbornyl”), bicyclo[2.2.2]octyl, and the like.
  • spiroalkyl refers to a structure consisting of two cycloalkyl moieties that have exactly one atom in common. Examples include, but are not limited to, spiro[4.5]decyl, spiro[2.3]hexyl, and the like.
  • heterocycloalkyl refers to a bicycloalkyl structure in which at least one carbon atom is replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur.
  • heterospiroalkyl refers to a spiroalkyl structure in which at least one carbon atom is replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur.
  • alkenyl refers to an ethylenically unsaturated hydrocarbon group, straight or branched chain, having 1 or 2 ethylenic bonds, for example vinyl, allyl, 1-butenyl, 2-butenyl, isopropenyl, 2-pentenyl, and the like.
  • cycloalkenyl refers to a cyclic aliphatic 3 to 12 ring structure, optionally substituted with alkyl, hydroxy and halo, having 1 or 2 ethylenic bonds such as methylcyclopropenyl, trifluoromethylcyclopropenyl, cyclopentenyl, cyclohexenyl, 1 ,4-cyclohexadienyl, and the like.
  • alkynyl refers to an unsaturated hydrocarbon group, straight or branched, having at least one acetylenic bond, for example ethynyl, propargyl, and the like.
  • aryl refers to an all-carbon monocyclic, bicyclic, or polycyclic groups of 6 to 12 carbon atoms having a completely conjugated pi-electron system, which may be optionally substituted.
  • aryl examples include, but are not limited to, phenyl, 4-chlorophenyl, 4- fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3- methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3-methoxyphenyl, 2,4-dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6-trichlorophenyl, 4-methoxyphenyl, naphthyl, 2- chloronaphthyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl, and 2-iodo-4-methylphenyl.
  • heteroaryl refer to a substituted or unsubstituted monocyclic, bicyclic, or polycyclic group of 5 to 12 ring atoms containing one or more ring heteroatoms selected from N, O, and S, the remaining ring atoms being C, and, in addition, having a completely conjugated pi-electron system.
  • heteroaryl rings examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
  • heteroaryl also include heteroaryl rings with fused carbocyclic ring systems that are partially or fully unsaturated, such as a benzene ring, to form a benzofused heteroaryl.
  • heteroaryl include fused 5-6, 5-5, 6-6 ring systems, optionally possessing one nitrogen atom at a ring junction.
  • examples of such hetaryl rings include, but are not limited to, pyrrolopyrimidinyl, imidazo[1 ,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, imidazo[4,5-b]pyridine, pyrrolo[2,1-f][1 ,2,4]triazinyl, and the like.
  • Heteroaryl groups may be attached to other groups through their carbon atoms or the heteroatom(s), if applicable. For example, pyrrole may be connected at the nitrogen atom or at any of the carbon atoms.
  • heterocycloalkyl refers to a substituted or unsubstituted monocyclic, bicyclic, or polycyclic ring group having in the ring(s) of 3 to 12 ring atoms, in which one or more ring atoms are heteroatoms selected from N, O, and S, the remaining ring atoms being C.
  • the rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system.
  • heterocycloalkyl rings examples include azetidine, oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thietane, thiazolidine, oxazolidine, oxazetidine, pyrazolidine, isoxazolidine, isothiazolidine, tetrahydrothiophene, tetrahydrothiopyran, thiepane, thiocane, azetidine, pyrrolidine, piperidine, N-methylpiperidine, azepane, 1 ,4-diazapane, azocane, [1 ,3]dioxane, oxazolidine, piperazine, homopiperazine, morpholine, thiomorpholine, 1 ,2,3,6-tetrahydropyridine and the like.
  • heterocycloalkyl rings include the oxidized forms of the sulfur-containing rings.
  • tetrahydrothiophene-1 -oxide, tetrahydrothiophene-1 ,1 -dioxide, thiomorpholine-1 -oxide, thiomorpholine-1 ,1 -dioxide, tetrahydrothiopyran-1 -oxide, tetrahydrothiopyran-1 ,1 -dioxide, thiazolidine-1 -oxide, and thiazolidine-1 ,1 -dioxide are also considered to be heterocycloalkyl rings.
  • heterocycloalkyl also includes fused ring systems and can include a carbocyclic ring that is partially or fully unsaturated, such as a benzene ring, to form benzofused heterocycloalkyl rings.
  • a carbocyclic ring that is partially or fully unsaturated, such as a benzene ring, to form benzofused heterocycloalkyl rings.
  • benzene ring to form benzofused heterocycloalkyl rings.
  • 3,4-dihydro-1 ,4-benzodioxine tetrahydroquinoline, tetrahydroisoquinoline and the like.
  • heterocycloalkyl also includes heterobicycloalkyl, heteropolycycloalkyl, or heterospiroalkyl, which are bicycloalkyl, polycycloalkyl, or spiroalkyl, in which one or more carbon atom(s) are replaced by one or more heteroatoms selected from O, N, and S.
  • x-y indicates a moiety containing from x to y atoms, e.g., 5- 6 heterocycloalkyl means a heterocycloalkyl having five or six ring members.
  • alkoxy includes both branched and straight chain terminal alkyl groups attached to a bridging oxygen atom. Typical alkoxy groups include methoxy, ethoxy, n- propoxy, isopropoxy, tert-butoxy and the like.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium slats.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines.
  • Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N',N'- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine,
  • the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • citric, hydrobromic, formic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids Particularly preferred are formic and hydrochloric acid.
  • the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure especially at least 98% pure (% are on a weight for weight basis).

Abstract

L'invention porte sur des composés de Formule I, telle que présentée ci-dessous ou définie dans la description : des sels pharmaceutiquement acceptables, synthèses, intermédiaires, formulations de ces composés et des méthodes de traitement de maladie par ces composés, y compris des cancers médiés au moins en partie par Ron et/ou Met.
PCT/US2009/065058 2008-11-20 2009-11-19 Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées WO2010059771A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09756112A EP2356116A1 (fr) 2008-11-20 2009-11-19 Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
JP2011537600A JP2012509342A (ja) 2008-11-20 2009-11-19 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
US13/130,113 US8592448B2 (en) 2008-11-20 2009-11-19 Substituted pyrrolo[2,3-b]-pyridines and -pyrazines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11637508P 2008-11-20 2008-11-20
US61/116,375 2008-11-20

Publications (1)

Publication Number Publication Date
WO2010059771A1 true WO2010059771A1 (fr) 2010-05-27

Family

ID=41549895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/065058 WO2010059771A1 (fr) 2008-11-20 2009-11-19 Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées

Country Status (4)

Country Link
US (1) US8592448B2 (fr)
EP (1) EP2356116A1 (fr)
JP (1) JP2012509342A (fr)
WO (1) WO2010059771A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143645A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinase bicycliques fusionnés
WO2011143646A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
WO2012127506A1 (fr) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Composés tricycliques substitués; compositions et applications médicinales correspondantes
WO2012158658A1 (fr) 2011-05-16 2012-11-22 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
JP2013543883A (ja) * 2010-11-29 2013-12-09 アステックス、セラピューティックス、リミテッド 癌疾患の治療のためのｆｇｆｒキナーゼ阻害剤としての置換ベンゾピラジン誘導体
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
CN104710417A (zh) * 2013-12-11 2015-06-17 上海科州药物研发有限公司 氮杂吲哚类衍生物及其合成方法
US9303030B2 (en) 2012-05-30 2016-04-05 Astex Therapeutics Limited Compounds
US9303029B2 (en) 2011-10-28 2016-04-05 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9309241B2 (en) 2011-10-28 2016-04-12 Astex Therapeutics Ltd Naphthyridine derivative compounds
US9309242B2 (en) 2011-10-28 2016-04-12 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
CN105712992A (zh) * 2012-09-29 2016-06-29 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
EP3037421A1 (fr) * 2008-11-25 2016-06-29 University Of Rochester Inhibiteurs de mlk et procédés d'utilisation
US9439896B2 (en) 2011-10-28 2016-09-13 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
US9447098B2 (en) 2012-05-30 2016-09-20 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US9464071B2 (en) 2010-04-30 2016-10-11 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US9493426B2 (en) 2013-04-26 2016-11-15 Astex Therapeutics Limited Quinazolinone derivatives useful as FGFR kinase modulators
US9902714B2 (en) 2014-03-26 2018-02-27 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
WO2020015744A1 (fr) 2018-07-19 2020-01-23 南京明德新药研发有限公司 Dérivé d'azaindole et son utilisation en tant qu'inhibiteur de fgfr et de c-met
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10898482B2 (en) 2015-02-10 2021-01-26 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
WO2021143875A1 (fr) 2020-01-15 2021-07-22 南京明德新药研发有限公司 Forme cristalline d'un dérivé d'azaindole et son application
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089280A1 (fr) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Composés alcynyle et leurs procédés d'utilisation

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004607A1 (fr) 2003-07-02 2005-01-20 Sugen, Inc. Arylmethyle triazolo et imidazopyrazines inhibiteurs de c-met
WO2005010005A1 (fr) 2003-07-02 2005-02-03 Sugen, Inc. Composés de triazolotriazine et utilisations de ceux-ci
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060046991A1 (en) 2004-08-26 2006-03-02 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US20060128724A1 (en) 2004-08-26 2006-06-15 Agouron Pharmaceuticals, Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2007002325A1 (fr) * 2005-06-22 2007-01-04 Plexxikon, Inc. Composes et methodes de modulation de la kinase et instructions afferentes
US20070032519A1 (en) 2005-05-17 2007-02-08 Chao Zhang Compounds modulating c-kit and c-fms activity and uses therefor
US20070043068A1 (en) 2004-07-27 2007-02-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20070049615A1 (en) 2003-12-19 2007-03-01 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US20070060633A1 (en) 2005-06-10 2007-03-15 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20070123535A1 (en) 2005-11-30 2007-05-31 Roche Palo Alto Llc 3-Amino-1-arylpropyl azaindoles and uses thereof
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
US7230098B2 (en) 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
WO2007067537A1 (fr) 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Composés inhibant les pyrrolopyridine kinases
WO2007075567A1 (fr) 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines en tant que modulateurs de la tyrosine kinase
WO2007132308A1 (fr) 2006-05-11 2007-11-22 Pfizer Products Inc. Dérivés de triazolopyrazine utiles en tant qu'agents anti-cancereux
WO2007138472A2 (fr) 2006-05-30 2007-12-06 Pfizer Products Inc. Dérivés de la triazolopyridazine
US20070287711A1 (en) 2004-07-27 2007-12-13 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
WO2008008539A2 (fr) 2006-07-14 2008-01-17 Amgen Inc. Dérivés hétérocycliques condensés et procédés d'utilisation
WO2008051808A2 (fr) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Triazoles bicycliques en tant que modulateurs de protéine kinase
WO2008051805A2 (fr) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Modulateurs de protéines kinases à base de triazolopyridazines

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
MXPA03011998A (es) 2001-06-23 2005-07-01 Aventis Pharma Inc Pirrolopirimidinas como inhibidores de protein cinasa.
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
WO2003082868A1 (fr) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n pour le traitement de troubles neurodegeneratifs
EP1569899B1 (fr) 2002-12-10 2006-06-28 Wyeth Derives substitues de l'acide 3-alkyl- et 3-arylalkyl-1h-indol-1-yl-acetique en tant qu'inhibiteurs de l'inhibiteur de l'activateur du plasminogene-1 (pai-1)
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
CA2573573A1 (fr) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Modulateurs heterocycliques a cycles fusionnes pour les kinases
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP2008510792A (ja) 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
AU2006323025B2 (en) 2005-12-05 2012-07-05 Pfizer Products Inc. Polymorphs of a c-Met/HGFR inhibitor
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
PT2057125E (pt) 2006-08-16 2011-05-31 Hoffmann La Roche Inibidores n?o nucle?sidos de transcriptase inversa
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US8639558B2 (en) 2006-09-25 2014-01-28 International Business Machines Corporation Providing markdown item pricing and promotion calendar
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
GB0621607D0 (en) 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2008080001A2 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et procédés pour la modulation de kinases et indications pour celle-ci
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008088881A1 (fr) 2007-01-19 2008-07-24 Xcovery, Inc. Composés inhibiteurs de kinase
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
KR101610415B1 (ko) 2007-12-21 2016-04-07 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
CN101918079A (zh) 2008-01-22 2010-12-15 默克专利有限公司 蛋白激酶抑制剂及其用途
JP5699075B2 (ja) 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
EP2349328A1 (fr) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Méthodes de traitement du cancer
PE20120184A1 (es) 2009-03-11 2012-03-28 Plexxikon Inc Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas raf
WO2011143646A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230098B2 (en) 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
WO2005010005A1 (fr) 2003-07-02 2005-02-03 Sugen, Inc. Composés de triazolotriazine et utilisations de ceux-ci
WO2005004607A1 (fr) 2003-07-02 2005-01-20 Sugen, Inc. Arylmethyle triazolo et imidazopyrazines inhibiteurs de c-met
US20070049615A1 (en) 2003-12-19 2007-03-01 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20070043068A1 (en) 2004-07-27 2007-02-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20070287711A1 (en) 2004-07-27 2007-12-13 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US20060046991A1 (en) 2004-08-26 2006-03-02 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US20060128724A1 (en) 2004-08-26 2006-06-15 Agouron Pharmaceuticals, Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
US20070032519A1 (en) 2005-05-17 2007-02-08 Chao Zhang Compounds modulating c-kit and c-fms activity and uses therefor
US20070060633A1 (en) 2005-06-10 2007-03-15 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2007002325A1 (fr) * 2005-06-22 2007-01-04 Plexxikon, Inc. Composes et methodes de modulation de la kinase et instructions afferentes
US20070123535A1 (en) 2005-11-30 2007-05-31 Roche Palo Alto Llc 3-Amino-1-arylpropyl azaindoles and uses thereof
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
WO2007067537A1 (fr) 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Composés inhibant les pyrrolopyridine kinases
WO2007075567A1 (fr) 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines en tant que modulateurs de la tyrosine kinase
WO2007132308A1 (fr) 2006-05-11 2007-11-22 Pfizer Products Inc. Dérivés de triazolopyrazine utiles en tant qu'agents anti-cancereux
WO2007138472A2 (fr) 2006-05-30 2007-12-06 Pfizer Products Inc. Dérivés de la triazolopyridazine
WO2008008539A2 (fr) 2006-07-14 2008-01-17 Amgen Inc. Dérivés hétérocycliques condensés et procédés d'utilisation
WO2008051808A2 (fr) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Triazoles bicycliques en tant que modulateurs de protéine kinase
WO2008051805A2 (fr) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Modulateurs de protéines kinases à base de triazolopyridazines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG ET AL., J. APPL. POLY. SCI., vol. 109, no. 5, 2008, pages 3369 - 3375

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037421A1 (fr) * 2008-11-25 2016-06-29 University Of Rochester Inhibiteurs de mlk et procédés d'utilisation
US9814704B2 (en) 2008-11-25 2017-11-14 The University Of Rochester Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors
US9464071B2 (en) 2010-04-30 2016-10-11 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US10519137B2 (en) 2010-04-30 2019-12-31 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US9850228B2 (en) 2010-04-30 2017-12-26 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
WO2011143646A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
CN102971316A (zh) * 2010-05-14 2013-03-13 Osi药物有限责任公司 稠双环激酶抑制剂
US8445510B2 (en) 2010-05-14 2013-05-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
WO2011143645A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinase bicycliques fusionnés
US9856236B2 (en) 2010-11-29 2018-01-02 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9290478B2 (en) 2010-11-29 2016-03-22 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
JP2013543883A (ja) * 2010-11-29 2013-12-09 アステックス、セラピューティックス、リミテッド 癌疾患の治療のためのｆｇｆｒキナーゼ阻害剤としての置換ベンゾピラジン誘導体
WO2012127506A1 (fr) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Composés tricycliques substitués; compositions et applications médicinales correspondantes
US9187473B2 (en) 2011-03-30 2015-11-17 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
US9962382B2 (en) 2011-03-30 2018-05-08 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
US9669028B2 (en) 2011-03-30 2017-06-06 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
WO2012158658A1 (fr) 2011-05-16 2012-11-22 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
US9309241B2 (en) 2011-10-28 2016-04-12 Astex Therapeutics Ltd Naphthyridine derivative compounds
US10039759B2 (en) 2011-10-28 2018-08-07 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
US9439896B2 (en) 2011-10-28 2016-09-13 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
US9527844B2 (en) 2011-10-28 2016-12-27 Astex Therapeutics Limited Naphthyridine derivative compounds
US10052320B2 (en) 2011-10-28 2018-08-21 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US10045982B2 (en) 2011-10-28 2018-08-14 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
US9757364B2 (en) 2011-10-28 2017-09-12 Astex Therapeutics Ltd Naphthyridine derivative compounds
US9309242B2 (en) 2011-10-28 2016-04-12 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
US9303029B2 (en) 2011-10-28 2016-04-05 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
US10272087B2 (en) 2012-05-30 2019-04-30 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US9303030B2 (en) 2012-05-30 2016-04-05 Astex Therapeutics Limited Compounds
US9737544B2 (en) 2012-05-30 2017-08-22 Astex Therapeutics Limited Compounds
US9447098B2 (en) 2012-05-30 2016-09-20 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
CN105712992A (zh) * 2012-09-29 2016-06-29 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US9493426B2 (en) 2013-04-26 2016-11-15 Astex Therapeutics Limited Quinazolinone derivatives useful as FGFR kinase modulators
CN104710417A (zh) * 2013-12-11 2015-06-17 上海科州药物研发有限公司 氮杂吲哚类衍生物及其合成方法
US10716787B2 (en) 2014-03-26 2020-07-21 Astex Therapeutics Ltd Combinations
US10421747B2 (en) 2014-03-26 2019-09-24 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
US11918576B2 (en) 2014-03-26 2024-03-05 Astex Therapeutics Ltd Combination of an FGFR inhibitor and a CMET inhibitor
US9902714B2 (en) 2014-03-26 2018-02-27 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10898482B2 (en) 2015-02-10 2021-01-26 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US11684620B2 (en) 2015-02-10 2023-06-27 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2020015744A1 (fr) 2018-07-19 2020-01-23 南京明德新药研发有限公司 Dérivé d'azaindole et son utilisation en tant qu'inhibiteur de fgfr et de c-met
CN115052877A (zh) * 2020-01-15 2022-09-13 深圳市瓴方生物医药科技有限公司 一种氮杂吲哚衍生物的晶型及其应用
WO2021143875A1 (fr) 2020-01-15 2021-07-22 南京明德新药研发有限公司 Forme cristalline d'un dérivé d'azaindole et son application
CN115052877B (zh) * 2020-01-15 2023-08-22 无锡瓴方生物医药科技有限公司 一种氮杂吲哚衍生物的晶型及其应用
JP7432739B2 (ja) 2020-01-15 2024-02-16 无錫▲りん▼方生物医薬科技有限公司 アザインドール誘導体の結晶形及びその応用
US11919898B2 (en) 2020-01-15 2024-03-05 Shenzhen Lingfang Biotech Co., Ltd. Crystal form of azaindole derivative and use thereof

Also Published As

Publication number Publication date
JP2012509342A (ja) 2012-04-19
US20110224191A1 (en) 2011-09-15
US8592448B2 (en) 2013-11-26
EP2356116A1 (fr) 2011-08-17

Similar Documents

Publication Publication Date Title
US8592448B2 (en) Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
JP5820472B2 (ja) 縮合二環式キナーゼ阻害剤
ES2451024T3 (es) Furo y tieno[3,2-c]piridinas
KR20190056435A (ko) 치환된 1H-이미다조[4,5-b]피리딘-2(3H)-온 및 GLUN2B 수용체 조절제로서의 이의 용도
US20130072495A1 (en) Fused bicyclic kinase inhibitors
JP2016537366A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
ES2816003T3 (es) Compuestos de heteroaril carboxamida como inhibidores de RIPK2
WO2021190615A1 (fr) Composés utilisés en tant qu'inhibiteurs de la caséine kinase
JP2013519681A (ja) ７−アミノフロピリジン誘導体
KR20210069080A (ko) 모노아실글리세롤 리파아제 조절제
BR112021005936A2 (pt) moduladores de monoacilglicerol lipase
WO2021224320A1 (fr) Nouveaux inhibiteurs macrocycliques de la lrrk2 kinase
US20140088114A1 (en) Fused bicyclic kinase inhibitors
JP2019530740A (ja) ピリジン並びに５員芳香環系化合物、その製造方法及び使用
JP2023541465A (ja) カゼインキナーゼ１デルタモジュレーター
EA041386B1 (ru) Спироциклические соединения и способы их получения и применения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09756112

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011537600

Country of ref document: JP

Ref document number: 13130113

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009756112

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009756112

Country of ref document: EP